Kamata Kotoe, Morioka Nobutada, Maruyama Takashi, Komayama Noriaki, Nitta Masayuki, Muragaki Yoshihiro, Kawamata Takakazu, Ozaki Makoto
Department of Anesthesiology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.
Department of Neurosurgery, Neurological Institute, Tokyo Women's Medical University, Tokyo, Japan.
J Anesth. 2016 Dec;30(6):941-948. doi: 10.1007/s00540-016-2243-9. Epub 2016 Aug 29.
Intraoperative vomiting leads to serious respiratory complications that could influence the surgical decision-making process for awake craniotomy. However, the use of antiemetics is still limited in Japan. The aim of this study was to investigate the effect of prophylactically administered single low-dose dexamethasone on the incidence of vomiting during awake craniotomy. The frequency of hyperglycemia was also examined.
We conducted a retrospective case review of awake craniotomy for glioma resection between 2012 and 2015.
Of the 124 patients, 91 were included in the analysis. Dexamethasone was not used in 43 patients and the 48 remaining patients received an intravenous bolus of 4.95 mg dexamethasone at anesthetic induction. Because of stable operating conditions, no one required conscious sedation throughout functional mapping and tumor resection. Although dexamethasone pretreatment reduced the incidence of intraoperative vomiting (P = 0.027), the number of patients who complained of nausea was comparable (P = 0.969). No adverse events related to vomiting occurred intraoperatively. Baseline blood glucose concentration did not differ between each group (P = 0.143), but the samples withdrawn before emergence (P = 0.018), during the awake period (P < 0.0001) and at the end of surgery (P < 0.0001) showed significantly higher glucose levels in the dexamethasone group. Impaired wound healing was not observed in either group.
A single low-dose of dexamethasone prevents intraoperative vomiting for awake craniotomy cases. However, as even a small dose of dexamethasone increases the risk for hyperglycemia, antiemetic prophylaxis with dexamethasone should be administered after careful consideration. Monitoring of perioperative blood glucose concentration is also necessary.
术中呕吐会导致严重的呼吸并发症,进而可能影响清醒开颅手术的手术决策过程。然而,在日本,止吐药的使用仍然有限。本研究的目的是探讨预防性单次低剂量地塞米松对清醒开颅手术期间呕吐发生率的影响。同时还研究了高血糖的发生频率。
我们对2012年至2015年间行清醒开颅胶质瘤切除术的病例进行了回顾性分析。
124例患者中,91例纳入分析。43例患者未使用地塞米松,其余48例患者在麻醉诱导时静脉推注4.95mg地塞米松。由于手术条件稳定,在整个功能定位和肿瘤切除过程中,无人需要清醒镇静。虽然地塞米松预处理降低了术中呕吐的发生率(P = 0.027),但主诉恶心的患者数量相当(P = 0.969)。术中未发生与呕吐相关的不良事件。两组间基线血糖浓度无差异(P = 0.143),但在苏醒前(P = 0.018)、清醒期(P < 0.0001)和手术结束时(P < 0.0001)采集的样本显示,地塞米松组的血糖水平显著更高。两组均未观察到伤口愈合受损。
单次低剂量地塞米松可预防清醒开颅手术中的术中呕吐。然而,即使小剂量地塞米松也会增加高血糖风险,因此应在仔细考虑后使用地塞米松进行止吐预防。围手术期血糖浓度监测也很有必要。